Actively Recruiting
Value of 68Ga-FAPI PET/CT Imaging to Evaluate Treatment Response in Patients with Advanced Unresectable Hepatocellular Carcinoma Undergoing Systemic Antitumor Therapy
Led by Ruijin Hospital · Updated on 2024-12-24
40
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research evaluates the use of 68Ga-FAPI PET/CT imaging to assess how well systemic antitumor treatments work for patients with advanced hepatocellular carcinoma that cannot be surgically removed. The study focuses on comparing imaging results with tissue analysis to better understand treatment responses in this condition. It involves adult patients between 18 and 75 years old diagnosed with this advanced liver cancer. Before starting treatment, all participants will have a 68Ga-FAPI PET/CT scan to capture detailed images of their cancer. After completing three months of systemic antitumor therapy, they will undergo a second PET/CT scan. Researchers will use these scans to measure changes in the cancer and compare them with pathological results, considered the gold standard, to evaluate treatment effectiveness. Participants will have their basic information, medical history, and contact details recorded at enrollment. Imaging response measurements and standardized uptake values will be assessed within one week of enrollment and again after up to three months of treatment. The study includes careful monitoring of responses to therapy and aims to gather comprehensive data on how well the imaging technique correlates with actual tumor changes over time.
CONDITIONS
Official Title
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients.
- Signed and dated informed consent form.
- Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- Aged 18-75 years old.
You will not qualify if you...
- Serious illnesses such as severe heart and lung failure, severe bone marrow suppression, or severe liver and kidney dysfunction.
- Intestinal perforation or complete intestinal obstruction.
- Pregnant women, women who may be pregnant, or women who are breastfeeding.
- Persons unwilling or unable to comply with study requirements.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
J
Jiajia Hu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here